Crafting Bespoke Bispecific Antibodies to Outsmart SARS-CoV-2’s Shifty Nature

February 21, 2024

Featured image for “Crafting Bespoke Bispecific Antibodies to Outsmart SARS-CoV-2’s Shifty Nature”

As the protean SARS-CoV-2 virus continues spinning troublesome new variants driving successive global waves of contagious COVID-19 illness, intense R&D spotlight shines on innovative antibody engineering strategies to keep pace. Custom-designing bispecific neutralizing antibodies offers particular promise as adaptable anti-coronavirus countermeasures by integrating diverse functionalities within singular therapies.

This article explores the allure of strategic bispecific antibodies against this shifty pandemic nemesis, highlighting recent efforts fusing distinct neutralizing antibody pairs to create multi-actives countermeasures thwarting viral immune evasion tactics.

The Perpetual Arms Race Against Shape-Shifting SARS-CoV-2

The foremost challenge complicating control of COVID-19 revolves around the intrinsic mutability of positive-strand RNA viruses like SARS-CoV-2 which frequently mutate during replication. Beneficial mutations enabling spike proteins to resist neutralization get naturally selected as novel variants overtaking predecessors.

This forces continual updating of antivirals and antibody treatments optimized against earlier versions while updating strain-matched vaccines – an endless cycle.

So sustainable solutions necessitate anticipating this adaptability by crafting intelligently engineered antibody therapies to stay a step ahead.

Bispecific Antibodies Offer Bespoke Viral Recognition

Unlike single monoclonal antibodies that target a singular viral epitope, bispecific antibodies integrate two unique monoclonals using protein engineering to create single Y-shaped immunotherapies simultaneously able to attach two independent antigen regions.

Advantages of such dual-action modalities against threats like SARS-CoV-2 include:

  • Heightened neutralization potency
  • Expanded strain coverage
  • Resistance to single mutations conferring antibody evasion

Thereby bispecific platforms pave exciting terrain for keeping up with this virus’ notorious evolutionary bend.

Pioneering a Potent Anti-SARS-CoV-2 Bispecific Antibody

In a high-profile 2022 study, researchers strategically combined two human neutralizing monoclonal antibodies – B38 and H4 – with non-overlapping binding sites on the SARS-CoV-2 spike protein to create a potent bispecific antibody.

The B38 and H4 Monoclonal Antibody Components

  • B38 attaches to the spike receptor binding domain (RBD), blocking engagement with the host ACE2 receptor.
  • H4 binds a glycosylated region on the spike N-terminal domain, obstructing viral fusion machinery.

Neither antibody interferes with the other’s binding when attached simultaneously.

Creating the Engineered Bispecific Format

Using genetic engineering approaches, the variable heavy and light chain sequences conferring B38 and H4’s targeting specificities were isolated from their original IgG backbones and fused into a single bispecific scaffold.

This enabled concurrent engagement of two distinct spike regions via a bespoke integrated architecture.

Testing Anti-Viral Potency Against SARS-CoV-2

Excitingly, the hybrid B38-H4 bispecific antibody exhibited marked improvements interfering with SARS-CoV-2 infection of cultured human cells compared to either parent monoclonal alone, highlighting synergistic effects.

Additional assessments confirmed:

  • Strong neutralization against the original viral strain as well as Alpha, Beta, Gamma and Delta variants in live virus assays.
  • Protection against disease in a mouse model of lethal SARS-CoV-2 infection.
  • Binding capacities unaffected by many new Omicron mutations.

So the uniquely engineered bispecific showed broad efficacy surpassing single antibodies – thwarting much of the virus’s notorious antigenic shape-shifting abilities to resist blockade.

Critically, being fully humanized itself avoids anti-drug antibody responses in patients that limit other antibody treatments.

Ongoing Innovation Expanding Utility

While pending essential clinical translation studies, this foundational bispecific antibody exemplifies the creative engineering possible against SARS-CoV-2 by integrating non-overlapping neutralizing mechanisms custom-designed for heightened synergistic potency.

Further Innovative Directions

Moreover, active innovation by numerous groups continues expanding bispecific modalities against even trickier future viral mutants:

Targeting Multiple Spike Regions

  • Asproof-of-concepts, tri- and tetra-specific antibodies simultaneously harnessing three or more distinct spike nail targets anticipate countermeasures against strains dodging simpler bispecific versions over time.

Incorporating Conserved Viral Elements

  • Fusing RBD-specific arms with those targeting non-mutable viral components like the nucleocapsid to avoid ALL immune evasion remains an active pursuit.

So ongoing bispecific antibody elaboration continues gathering steam to sustainably thwart this virus’s endlessly troublesome evolutionary prowess.

Mobilizing Endogenous Antibody Reponses

Separately, mapping antibody reactivity profiles in COVID-19 recovered patients provides invaluable foundations guiding cutting-edge antibody engineering endeavors.

Highlights of key recovered patient “antibody atlas” insights include:

Infection Elicits Diverse Functional Response

  • Beyond spike interactions, patients produce antiviral antibodies targeting other SARS-CoV-2 proteins including membrane, envelope and nucleocapsid elements – although spike responses strongly predominate.

Neutralizing Activity Emerges Over Time

  • While non-neutralizing antibodies arise earliest post-infection, the most potently neutralizing antibodies take longer to mature – becoming detectable from a few weeks up to a year after recovery.

Neutralizer Breadth Varies Between Individuals

  • The specificity of elicited neutralizing responses differs among recovering individuals – some produce antibodies only blocking the infecting strain while other patients make antibodies effective even against variants they never directly encountered.

So comprehensively mapping the landscape of antiviral immunity ultimately generated after natural infection provides an invaluable guide towards engineering optimized bispecific antibodies deliberately integrating diverse desired functionalities.

Addressing Key Questions Around SARS-CoV-2 Bispecific Antibodies

How do bispecific antibodies improve on monoclonal antibodies against COVID-19?

By simultaneously attaching dual targets on SARS-CoV-2, bispecific antibodies exhibit enhanced neutralizing potency compared to individual component monoclonals alone. This lowers the dose required for efficacy and provides built-in redundancy against single viral mutations conferring antibody evasion.

What findings most excited researchers about the B38-H4 bispecific antibody?

The B38-H4 bispecific antibody showed broad efficacy thwarting infection by major SARS-CoV-2 variants of concern including Alpha, Beta and Delta – going beyond the original 2019 strain. This demonstrates the promise of engineering resilience against the virus’s shape-shifting adaptability into next-generation antibody therapies upfront.

What are key challenges still facing anti-SARS-CoV-2 bispecific antibodies?

Despite promising lab improvements, pivotal clinical studies are still needed examining whether experimental bispecific platforms translated into actual patient benefit in COVID-19 illness. Other hurdles include enhancing manufacturability of engineered antibodies, lowering production costs to ensure availability globally if efficacious, and evaluating safety.

How could mapping recovered patient antibody responses aid countermeasure designs?

Studying the diversity of neutralizing antibodies produced over time by different patients provides an invaluable blueprint highlighting viral vulnerabilities useful for deliberate integration into optimized bispecific therapies – especially antibodies effective even against emerging mutated strains.

Could multi-specific antibodies beyond bispecific formats prove useful?

Early multi-specific antibodies engaging three or more distinct spike epitopes in a single molecule anticipate eventual incremental gains in neutralization breadth and potency as SARS-CoV-2 evolves over time. Meanwhile, incorporating non-mutable viral components alongside spike arms could offer sustainable efficacy improvements.

In Summary…

  • Pioneering bispecific antibody engineering judiciously fuses two distinct neutralizing monoclonal components offers heightened blockade against the endlessly shape-shifting SARS-CoV-2 menace.
  • Simultaneous dual target virus engagement translates into synergistic improvements thwarting viral entry and fusion events.
  • Ongoing elaboration continues enhancing future-proofing of such platforms against emergent immune-evasive spike mutants.
  • Comprehensively mapping antiviral immunity profiles in recovering patients crucially guides optimal integrated functionalities.
  • So strategic bispecific antibody elaboration markers a high-potential avenue delivering enduring weapons for tipping the scales against this formidable pandemic nemesis.

Therefore, cross-disciplinary alliances coalescing antibody engineering with leading-edge immunology offer promise for sustaining decisive counterattack measures keeping apace of SARS-CoV-2’s travels along its incessant evolutionary trajectory.

Rate this post

Related articles


Cold Plasma System

The world's first handheld cold plasma device

Learn More

Made in USA